CD274 and lung carcinoma: We will discuss recent advancements in immunotherapy in lung cancer therapy, covering topics such as PD-1/PD-L1 checkpoint inhibitors, monoclonal antibodies that target cell surface receptors, antibody–drug conjugates, and bispecific antibodies.